200956-13-4 Usage
General Description
2-Bromo-4-(trifluoromethoxy)phenol, also known as trifluoromethoxyphenyl bromide, is a chemical compound with the formula C7H4BrF3O2. It is a white to light brown crystalline solid that is commonly used in the synthesis of pharmaceuticals and agrochemicals. 2-BROMO-4-(TRIFLUOROMETHOXY)PHENOL is used as a building block in organic synthesis, particularly in the production of drugs and herbicides. It is also known for its antimicrobial and antifungal properties, making it useful in the development of new pharmaceutical products. Additionally, it is used as an intermediate in the manufacture of specialty chemicals and other organic compounds. Overall, 2-Bromo-4-(trifluoromethoxy)phenol is a versatile chemical that has a wide range of applications in the pharmaceutical and agrochemical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 200956-13-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,0,9,5 and 6 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 200956-13:
(8*2)+(7*0)+(6*0)+(5*9)+(4*5)+(3*6)+(2*1)+(1*3)=104
104 % 10 = 4
So 200956-13-4 is a valid CAS Registry Number.
200956-13-4Relevant articles and documents
Use of NK-1 receptor antagonists for treating major depressive disorders
-
, (2008/06/13)
The present invention provides methods for the treatment of major depressive disorders comprising oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor
Stereocontrolled syntheses of epimeric 3-aryl-6-phenyl-1-oxa-7-azaspiro[4.5]decane NK-1 receptor antagonist precursors
Kulagowski, Janusz J.,Curtis, Neil R.,Swain, Christopher J.,Williams, Brian J.
, p. 667 - 670 (2007/10/03)
Equation presented Complementary stereoselective syntheses of individual C3 epimers of the NK-1 receptor antagonist precursor 1 have been developed. Both diastereomers were derived from the common intermediate 3; introduction of the 3S stereocenter in 1a
USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING BIPOLAR DISORDERS
-
, (2008/06/13)
The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-
